

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:116979 CAPLUS Full-text

DN 144:192031

TI Preparation of prostaglandin analogs as antiglaucoma agents

IN Old, David W.; Dinh, Danny T.; Burk, Robert M.

PA Allergan, Inc., USA

SO PCT Int. Appl., 47 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006014206	A1	20060209	WO 2005-US19408	20050531
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005270229	A1	20060209	AU 2005-270229	20050531
	CA 2571782	A1	20060209	CA 2005-2571782	20050531
	EP 1765785	A1	20070328	EP 2005-756187	20050531
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	US 2007054893	A1	20070308	US 2005-549959	20050915
PRAI	US 2004-585142P	P	20040702		
	US 2004-600180P	P	20040809		
	WO 2005-US19408	W	20050531		
OS	MARPAT 144:192031				
GI					



AB Prostaglandin analogs of formula I [A = (CH<sub>2</sub>)<sub>6</sub>, cis-CH<sub>2</sub>CH=CH(CH<sub>2</sub>)<sub>3</sub>, CH<sub>2</sub>C.tplbond.C(CH<sub>2</sub>)<sub>3</sub>; X = CO<sub>2</sub>H, substituted CONH<sub>2</sub>, etc.; J = CO, CHO<sub>H</sub>, CH<sub>2</sub>CHO<sub>H</sub>; E = alkyl, cycloalkyl, Ph, naphthyl] are prepared for the treatment of glaucoma. Thus, II had EC<sub>50</sub> value of 266 nM against hEP4.

IT 875299-82-4P 875299-83-5P 875299-84-6P  
875299-85-7P 875299-86-8P 875299-87-9P  
875299-88-0P 875299-89-1P 875299-90-4P  
875299-91-5P 875299-92-6P 875299-93-7P  
875299-94-8P 875299-95-9P 875299-96-0P  
875299-97-1P 875299-98-2P 875299-99-3P  
875300-00-8P 875300-01-9P 875300-02-0P  
875300-03-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of azepanone prostaglandin analogs as antiglaucoma agents)

RN 875299-82-4 CAPLUS

CN 5-Heptynoic acid, 7-[hexahydro-2-oxo-7-[(1E)-3-oxo-4-phenyl-1-butenyl]-1H-

azepin-1-yl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 875299-83-5 CAPLUS

CN 5-Heptynoic acid, 7-[hexahydro-2-oxo-7-[(1E)-3-oxo-4-phenyl-1-butenyl]-1H-azepin-1-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 875299-84-6 CAPLUS

CN 5-Heptynoic acid, 7-[hexahydro-2-[(1E)-3-hydroxy-4-phenyl-1-butenyl]-7-oxo-1H-azepin-1-yl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 875299-85-7 CAPLUS


CN 5-Heptynoic acid, 7-[hexahydro-2-[(1E)-3-hydroxy-4-phenyl-1-butenyl]-7-oxo-1H-azepin-1-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 875299-86-8 CAPLUS

CN 1H-Azepine-1-heptanoic acid, hexahydro-2-oxo-7-(3-oxo-4-phenylbutyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 875299-87-9 CAPLUS

CN 1H-Azepine-1-heptanoic acid, hexahydro-2-oxo-7-(3-oxo-4-phenylbutyl)- (9CI) (CA INDEX NAME)




RN 875299-88-0 CAPLUS

CN 1H-Azepine-1-heptanoic acid, hexahydro-2-(3-hydroxy-4-phenylbutyl)-7-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 875299-89-1 CAPLUS

CN 1H-Azepine-1-heptanoic acid, hexahydro-2-(3-hydroxy-4-phenylbutyl)-7-oxo- (9CI) (CA INDEX NAME)




RN 875299-90-4 CAPLUS

CN 5-Heptynoic acid, 7-[hexahydro-2-oxo-7-(3-oxo-4-phenylbutyl)-1H-azepin-1-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 875299-91-5 CAPLUS

CN 5-Heptynoic acid, 7-[hexahydro-2-oxo-7-(3-oxo-4-phenylbutyl)-1H-azepin-1-yl]- (9CI) (CA INDEX NAME)




RN 875299-92-6 CAPLUS

CN 5-Heptynoic acid, 7-[hexahydro-2-(3-hydroxy-4-phenylbutyl)-7-oxo-1H-azepin-1-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 875299-93-7 CAPLUS


CN 5-Heptynoic acid, 7-[hexahydro-2-(3-hydroxy-4-phenylbutyl)-7-oxo-1H-azepin-1-yl]- (9CI) (CA INDEX NAME)



RN 875299-94-8 CAPLUS

CN 1H-Azepine-1-heptanoic acid, hexahydro-2-oxo-7-[(1E)-3-oxo-4-phenyl-1-but enyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 875299-95-9 CAPLUS

CN 1H-Azepine-1-heptanoic acid, hexahydro-2-[(1E)-3-hydroxy-4-phenyl-1-but enyl]-7-oxo-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 875299-96-0 CAPLUS

CN 1H-Azepine-1-heptanoic acid, hexahydro-2-oxo-7-[(1E)-3-oxo-4-phenyl-1-but enyl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 875299-97-1 CAPLUS

CN 1H-Azepine-1-heptanoic acid, hexahydro-2-[(1E)-3-hydroxy-4-phenyl-1-but enyl]-7-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 875299-98-2 CAPLUS

CN 5-Heptenoic acid, 7-[hexahydro-2-[(1E)-3-hydroxy-4-phenyl-1-but enyl]-7-oxo-1H-azepin-1-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 875299-99-3 CAPLUS

CN 5-Heptenoic acid, 7-[hexahydro-2-[(1E)-3-hydroxy-4-phenyl-1-but enyl]-7-oxo-1H-azepin-1-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 875300-00-8 CAPLUS

CN 5-Heptenoic acid, 7-[hexahydro-2-oxo-7-(3-oxo-4-phenylbutyl)-1H-azepin-1-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 875300-01-9 CAPLUS

CN 5-Heptenoic acid, 7-[hexahydro-2-oxo-7-(3-oxo-4-phenylbutyl)-1H-azepin-1-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 875300-02-0 CAPLUS

CN 5-Heptenoic acid, 7-[hexahydro-2-(3-hydroxy-4-phenylbutyl)-7-oxo-1H-azepin-1-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 875300-03-1 CAPLUS

CN 5-Heptenoic acid, 7-[hexahydro-2-(3-hydroxy-4-phenylbutyl)-7-oxo-1H-azepin-1-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RE.CNT 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:128238 CAPLUS Full-text  
 DN 136:346449  
 TI Extraction of uranium(VI) and plutonium(IV) from nitric acid solutions by substituted cyclic amides  
 AU Suzuki, Shinichi; Tamura, Kazunari; Tachimori, Shoichi; Usui, Yoshiharu  
 CS Department of Material Science, Japan Atomic Energy Research Institute, Ibaraki, 319-1195, Japan  
 SO Solvent Extraction for the 21st Century, Proceedings of ISEC '99, Barcelona, Spain, July 11-16, 1999 (2001), Meeting Date 1999, Volume 1, 697-702. Editor(s): Cox, Michael; Hidalgo, Manuela; Valiente, Manuel. Publisher: Society of Chemical Industry, London, UK.  
 CODEN: 69CGL8  
 DT Conference  
 LA English  
 AB The following cyclic amides were used in the study: N-(2-ethyl)hexylcaprolactam (EHCLA), N-octyl-caprolactam (OCLA), 2-octyl-N-(2-ethyl)hexylcaprolactam (2OEHCLA), 3-octyl-N-(2-ethyl)hexylcaprolactam/5-octyl-N-(2-ethyl)hexylcaprolactam mixture (30,50EHCLA), and 3-octyl-N-octyl-caprolactam/5-octyl-N-octyl-caprolactam mixture (30,50OCLA). The extraction of U(VI) and Pu(IV) by the amides was investigated under various conditions. From the results of distribution ratio(DM) as functions of nitric acid and cyclic amide concns., the authors discussed the effects of the amides structure, i.e., the branched alkyl group attached nitrogen atom and position of substituted octyl group on the extraction behavior of U(VI) and Pu(IV). DU and DPu by OCLA is larger to small extant than that by EHCLA. OCLA and EHCLA resp. concentration of 1 M in dodecane have produced the third phase. By introducing an octyl group to ring part, the third phase disappeared due to the increase of hydrophobicity of cyclic amides. DU and DPu with 2OEHCLA were lower than that with the mixture of 30EHCLA and 50EHCLA. Steric hindrance caused by n-octyl group neighboring C=O to the extraction of Pu(IV) is larger than that of U(VI). In this paper, the relationship between the DM and ring structure, especially steric effect around oxygen donor atom of the amides.  
 IT 224295-68-5 224295-70-9  
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)  
 (uranium(VI) and plutonium(IV) solvent extraction from nitric acid solns.  
 by alkyl substituted caprolactams)  
 RN 224295-68-5 CAPLUS  
 CN 2H-Azepin-2-one, hexahydro-1,4-dioctyl- (9CI) (CA INDEX NAME)



RN 224295-70-9 CAPLUS  
 CN 2H-Azepin-2-one, hexahydro-1,6-dioctyl- (9CI) (CA INDEX NAME)




RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2001:414604 CAPLUS Full-text  
 DN 135:11460  
 TI Recovery of technetium from acidic solution by cyclic amide compounds  
 IN Tate Mori, Shoichi; Suzuki, Shinichi  
 PA Japan Atomic Energy Research Institute, Japan  
 SO Jpn. Kokai Tokkyo Koho, 5 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2001153995	A	20010608	JP 1999-333226	19991124
PRAI JP 1999-333226		19991124		


AB The invention relates to extraction and separation of Tc(VII) ion, suited for use in PUREX process to recover radioactive Tc, wherein the cyclic amide compds. are utilized for recovering the Tc from the acidic solution  
 IT 341497-95-8 341497-97-0  
 RL: TEM (Technical or engineered material use); USES (Uses)  
 (recovery of technetium from acidic solution by cyclic amide compds.)  
 RN 341497-95-8 CAPLUS  
 CN 2H-Azepin-2-one, hexahydro-1,3-dioctyl- (9CI) (CA INDEX NAME)




RN 341497-97-0 CAPLUS  
 CN 2H-Azepin-2-one, hexahydro-1,5-dioctyl- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1999:294086 CAPLUS Full-text  
 DN 130:357710  
 TI Solvent extraction of technetium(VII) by cyclic amides  
 AU Suzuki, S.; Tamura, K.; Tachimori, S.; Usui, Y.  
 CS Japan Atomic Energy Research Institute, Tokai, Japan  
 SO Journal of Radioanalytical and Nuclear Chemistry (1999), 239(2), 377-380  
 CODEN: JRNCDM; ISSN: 0236-5731  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 AB The extraction behavior of Tc(VII) with cyclic amides in n-dodecane from HNO<sub>3</sub> solution was studied. The amides investigated are N-(2-ethyl)hexylbutyrolactam, N-(2-ethyl)hexylvalerolactam, N-(2-ethyl)hexylcaprolactam, N-octylcaprolactam, a mixture of 3-octyl-N-(2-ethyl)hexylvalerolactam and 4-octyl-N-(2-ethyl)hexylvalerolactam (3,4-OEHVLA), 2-octyl-N-(2-ethyl)hexylcaprolactam, a mixture of 3-octyl-N-(2-ethyl)hexylcaprolactam and 5-octyl-N-(2-ethyl)hexylcaprolactam, and that of 3-octyl-N-octylcaprolactam and 5-octyl-N-octylcaprolactam. From the results of the distribution ratio of Tc(VII) as a function of acid concentration, cyclic amides concentration and HTcO<sub>4</sub> concentration, the effects of both the ring size of cyclic amide and structure of the substituents attached to different positions of the cyclic ring on the extraction behavior of Tc(VII) were discussed. A clear steric hindrance was observed. For applications, 3,4-OEHVLA is proposed as the best extractant for Tc from acidic solution  
 IT 224295-68-5  
 RL: NUU (Other use, unclassified); USES (Uses)  
     (solvent extraction of Tc(VII) by cyclic amides)  
 RN 224295-68-5 CAPLUS  
 CN 2H-Azepin-2-one, hexahydro-1,4-dioctyl- (9CI) (CA INDEX NAME)




IT 224295-70-9  
 RL: PEP (Physical, engineering or chemical process); PROC (Process)  
     (solvent extraction of Tc(VII) by cyclic amides)  
 RN 224295-70-9 CAPLUS  
 CN 2H-Azepin-2-one, hexahydro-1,6-dioctyl- (9CI) (CA INDEX NAME)




RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1999:223593 CAPLUS Full-text  
 DN 130:344063  
 TI Extraction of uranium (VI) and plutonium (IV) from nitric acid solution by substituted cyclic amides  
 AU Suzuki, Shinichi; Tamura, Kazunari; Tachimori, Shoichi; Usui, Yoshiharu  
 CS Department of Materials Science, Japan Atomic Energy Research Institute, Ibaraki, 319-1195, Japan  
 SO Solvent Extraction Research and Development, Japan (1999), 6, 72-79  
 CODEN: SERDEK; ISSN: 1341-7215  
 PB Japanese Association of Solvent Extraction  
 DT Journal  
 LA English  
 AB Eight substituted cyclic amides of butyrolactam, valerolactam, and caprolactam have been synthesized and the extraction of U(VI) and Pu(IV) by the amides was studied under various conditions. From the results of distribution ratio measurement for U(VI) and Pu(IV) (DU and DPu), as functions of HNO<sub>3</sub> and cyclic amide concns., the effects of the cyclic amide ring size and the structure of substituents attached to different positions in the cyclic ring on the extraction were discussed. N-(2-ethylhexyl)-butyrolactam (EHBLA), N-(2-ethylhexyl)-valerolactam (EHVLA) and N-(2-ethylhexyl)-caprolactam (EHCLA) at a concentration of 1 kmol/m<sup>3</sup> in dodecane produced a 3rd phase at relatively high HNO<sub>3</sub> concentration in the aqueous phase. By introducing an octyl group to the ring the 3rd phase disappeared. EHVLA extracted U(VI) and Pu(IV) more stronger than EHBLA and EHCLA. DU and DPu values for 2-octyl-N-(2-ethylhexyl)-caprolactam (2OEHCLA) were lower than for the mixture of 3-octyl-N-(2-ethylhexyl)- caprolactam (3OEHCLA) and 5-octyl-N-(2-ethylhexyl)-caprolactam (5OEHCLA). Steric hindrance by an n-octyl group next to the C=O group was greater in the extraction of Pu(IV) than U(VI).  
 IT 224295-68-5 224295-70-9  
 RL: NUU (Other use, unclassified); USES (Uses)  
     (extraction of uranium (VI) and plutonium (IV) from nitric acid solution by substituted cyclic amides)  
 RN 224295-68-5 CAPLUS  
 CN 2H-Azepin-2-one, hexahydro-1,4-dioctyl- (9CI) (CA INDEX NAME)



RN 224295-70-9 CAPLUS  
 CN 2H-Azepin-2-one, hexahydro-1,6-dioctyl- (9CI) (CA INDEX NAME)




RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 12; d his; log y

L2 HAS NO ANSWERS

L1 STR



G1 C,O,S

G2 C,S,P,Hy

G3 Cy,Ak

Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 23:41:37 ON 02 JUL 2007)

FILE 'REGISTRY' ENTERED AT 23:41:51 ON 02 JUL 2007

L1 STRUCTURE uploaded

L2 QUE L1

L3 0 S L2

L4 26 S L2 FUL

FILE 'CAPLUS' ENTERED AT 23:42:39 ON 02 JUL 2007

L5 5 S L4

FILE 'MARPAT' ENTERED AT 23:43:26 ON 02 JUL 2007

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

0.45 199.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY

SESSION

0.00 -3.90

STN INTERNATIONAL LOGOFF AT 23:43:58 ON 02 JUL 2007